Trump to impose pharma tariffs by August 1, semiconductors likely next
Donald Trump
said that he was likely to impose tariffs on pharmaceuticals as soon as the end of the month and that levies on
semiconductors
could come soon as well, suggesting that those import taxes could hit alongside broad "reciprocal" rates set for implementation on Aug. 1.
"Probably at the end of the month, and we're going to start off with a low tariff and give the pharmaceutical companies a year or so to build, and then we're going to make it a very high tariff," Trump told reporters Tuesday as he returned to Washington after attending an artificial intelligence summit in Pittsburgh.
Explore courses from Top Institutes in
Select a Course Category
Digital Marketing
Operations Management
Leadership
Data Science
Others
others
Design Thinking
Data Analytics
Degree
Management
MCA
Technology
Public Policy
Cybersecurity
MBA
CXO
Artificial Intelligence
Project Management
Product Management
Healthcare
healthcare
Data Science
PGDM
Finance
Skills you'll gain:
Digital Marketing Strategy
Search Engine Optimization (SEO) & Content Marketing
Social Media Marketing & Advertising
Data Analytics & Measurement
Duration:
24 Weeks
Indian School of Business
Professional Certificate Programme in Digital Marketing
Starts on
Jun 26, 2024
Get Details
Skills you'll gain:
Digital Marketing Strategies
Customer Journey Mapping
Paid Advertising Campaign Management
Emerging Technologies in Digital Marketing
Duration:
12 Weeks
Indian School of Business
Digital Marketing and Analytics
Starts on
May 14, 2024
Get Details
Trump also said his timeline for implementing tariffs on semiconductors was "similar" and that it was "less complicated" to impose levies on chips, without providing additional detail.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
[70%할인] 갱년기 배우 최명길이 강력추천하는 '이것' 오늘 상담신청 시 1개월치 무료증정!
리피어라
더 알아보기
Undo
At a Cabinet meeting earlier this month, Trump said he planned to impose a 50% tariff on copper in the coming weeks, and that he expected pharmaceutical tariffs to grow as high as 200% after giving companies a year to bring manufacturing back to the US. Trump has already announced investigations under Section 232 of the Trade Expansion Act of 1962 on drugs, arguing a flood of foreign imports was threatening national security.
Still, any tariffs could immediately impact drugmakers like
Eli Lilly
& Co.,
Merck
& Co. and
Pfizer Inc
. that produce drugs overseas - and risks driving up costs for US consumers. So does Trump's plans for semiconductor tariffs, which are expected to hit not only the chips themselves but popular products like Apple Inc. and Samsung Electronic Co Ltd. laptops and smartphones.
Live Events
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
First Post
16 minutes ago
- First Post
Columbia University reaches $220 million settlement with Trump over antisemitism concerns
Columbia University has agreed to pay $220 million to the federal government to settle investigations tied to antisemitism concerns and suspended research funding. The settlement follows months of scrutiny from the Trump administration over the university's handling of campus protests during the Israel-Hamas war. read more Columbia University has reached a $220 million settlement with the Trump administration to resolve federal investigations linked to antisemitism concerns and the suspension of research funding, the Ivy League institution announced on Wednesday. Under the agreement, Columbia will pay $200 million over three years to the federal government and an additional $21 million to settle separate investigations by the US Equal Employment Opportunity Commission. The deal follows months of federal scrutiny after allegations that the university failed to effectively address antisemitism on campus during the Israel-Hamas conflict that erupted in October 2023. STORY CONTINUES BELOW THIS AD In response to pressure from the Trump administration, Columbia agreed earlier this year to a set of reforms, including adopting a new definition of antisemitism and revising its student disciplinary procedures. Acting University President Claire Shipman called the settlement 'an important step forward,' saying it codifies the agreed changes while preserving the university's academic independence. The agreement does not include an admission of wrongdoing. At one point, Columbia faced the potential loss of billions in federal funding, including more than $400 million in research grants that had already been canceled. Shipman said the settlement restores the university's critical research partnership with the federal government while protecting its institutional values. As part of the deal, Columbia will also review its Middle East studies curriculum to ensure it is 'comprehensive and balanced,' hire new faculty at the Institute for Israel and Jewish Studies, and dismantle programs deemed to promote unlawful race-based outcomes, quotas, or diversity targets.
&w=3840&q=100)
First Post
16 minutes ago
- First Post
Supreme Court green lights Trump's removal of 3 Democrats from consumer safety panel
The US Supreme Court has allowed the removal of 3 Democratic members from the Consumer Product Safety Commission, siding with the Trump administration in a dispute over presidential authority. The decision overturns a lower court ruling that had reinstated the Biden-appointed officials. read more Ties between the US and Pakistan have improved under Donald Trump. File Photo/Reuters The US Supreme Court on Wednesday allowed the removal of three Democratic members of the Consumer Product Safety Commission (CPSC), siding with the Trump administration in a dispute over presidential authority. The three officials, appointed by President Biden to serve seven-year terms, were fired by Donald Trump in May. A federal judge had reinstated them, calling the firings unlawful, but the Supreme Court overturned that decision in response to an emergency appeal from the Justice Department. STORY CONTINUES BELOW THIS AD The administration argued that the CPSC, like other federal agencies, falls under presidential control—giving the president the power to remove commissioners without cause. The court's three liberal justices dissented. The CPSC, created in 1972, is tasked with protecting consumers by issuing recalls and enforcing product safety rules. By law, the five-member panel must be bipartisan, with no more than three commissioners from the president's party. The ruling reflects broader legal tensions over the extent of presidential power. In June, a Biden-appointed judge, Matthew Maddox, had ruled that the CPSC's structure offered some independence from the executive branch, unlike agencies where firings had been upheld. The case could eventually lead to a challenge of the 1935 Humphrey's Executor ruling, which held that presidents cannot fire members of independent agencies without cause. That decision has long frustrated conservatives, who argue federal agencies should answer directly to the president. Attorneys for the ousted commissioners warned that allowing such removals could undermine the agency's independence and its ability to function free from political pressure.
Time of India
25 minutes ago
- Time of India
‘Getting Future Fit, Tata Tripled Profit in 5 Years'
Tata group nearly doubled revenue, and more than tripled net profit and market cap over the past five years, when it spent ₹5.5 lakh crore to be 'future fit,' said Tata Sons chairman N Chandrasekaran , in the latest annual report. The group has sought to alter strategies that 'may have aged poorly with time and changing economic conditions.' Group revenue from all listed and unlisted entities was Rs 15.34 lakh crore in FY25, with net profit at Rs 1.13 lakh crore and market cap at Rs 37.84 lakh crore, according to the Tata Sons report. Explore courses from Top Institutes in Please select course: Select a Course Category Data Analytics Finance Healthcare MCA Data Science Digital Marketing Cybersecurity Management CXO MBA Degree Project Management Public Policy PGDM Operations Management others Others Technology Leadership Artificial Intelligence Design Thinking Product Management Data Science healthcare Skills you'll gain: Data Analysis & Visualization Predictive Analytics & Machine Learning Business Intelligence & Data-Driven Decision Making Analytics Strategy & Implementation Duration: 12 Weeks Indian School of Business Applied Business Analytics Starts on Jun 13, 2024 Get Details 'Tata group has been on a transformational journey towards financial and strategic fitness,' Chandrasekaran said in the report reviewed by ET. 'It is my deep conviction that we must be fit to perform. To do that, we must be honest that some decisions that might have appeared ideal when they were taken may have aged poorly... As a result, our mantra in the last few years was 'fitness first, velocity next'.' Some of the businesses have been cyclical, while uncertain geopolitics and economics have also been challenges. TCS continues to be the group profit engine. It accounted for 43% of group net profit in FY25. Tata Sons posted a 24% rise in FY25 revenue to Rs 5.92 lakh crore, while net profit fell 17% to Rs 28,898 crore from a year ago. There was no explanation given for the decline. Tata Sons dividend, however, doubled to Rs 1,414.5 crore from Rs 707.2 crore in FY24. The holding company had 323 subsidiaries, 39 associates and 32 joint ventures in FY25. On a standalone basis, revenue fell 12% to Rs 38,834.6 crore in FY25, from Rs43,893 crore in the previous year. That FY24 number had included a profit of Rs 9,375.7 crore from the sale of investments. Profit after tax fell 24% to Rs 26,231.7 crore in FY25. 'Financial discipline is vital, as mistakes are costly distractions from our purpose. Even as parts of Tata group drive unprecedented ambition in new industries, I stay committed to driving predictability in the rest of our portfolio,' said Chandrasekaran, who drew a remuneration of Rs 155.61 crore, including commission, during FY25, a 15% jump from the year before, putting him among India's highest paid CEOs.
